ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive uterine cancer: targeted combo shows promise in phase 3 trial
Disease control Recruiting nowThis study tests whether adding two targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can shrink tumors and stop HER2-positive endometrial cancer from coming back. About 360 people with stage I to IV cancer will receive either chemo alone or chemo plus the targ…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
New hope for aggressive endometrial cancer: drug combo targets obesity link
Disease control Recruiting nowThis early-stage trial is testing the safety of combining two drugs, atezolizumab and ONC201, for people with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see how body weight affects treatment. The goal is to find the best …
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests two experimental drugs (M1774 and ZEN-3694) together in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see how well the combination works. About 65 participants will take part to help determine if this…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Immunotherapy duo shows promise against tough uterine cancer
Disease control Recruiting nowThis study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (called dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against one drug alone (nivolumab) to see which shrinks tumors better. About …
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Shorter radiation may ease burden for endometrial cancer patients
Symptom relief Recruiting nowThis study compares a shorter course of internal radiation (vaginal cuff brachytherapy) to the standard longer course for people with early-stage endometrial cancer. The goal is to see if the shorter treatment improves quality of life and reduces financial stress. About 188 parti…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: University of Utah • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC